News

Healthcare providers should not base cancer care with immune checkpoint inhibitors on gender, according to recent study findings.

Trebek's current outcome could offer a source of hope for patients with pancreatic cancer, who typically have poor prognoses.

The FDA has approved the R2 regimen of lenalidomide (Revlimid) plus rituximab (Rituxan) for use in patients with previously treated follicular lymphoma and marginal zone lymphoma (MZL).

In non–small cell lung cancer (NSCLC), KRAS G12 mutations have been historically difficult to target, and research efforts dedicated to the development of effective targeted therapies for NRG1 fusions have not been successful. However, several biopharmaceutical companies are in the early stages of addressing that challenge, explained Sai-Hong I. Ou, MD, PhD.

Genetic and genomic testing are becoming more popular and useful in the cancer space.

There may be a correlation between androgen deprivation therapy and cardiac complications, but more research is still needed.

The FDA has approved the PI3K inhibitor alpelisib (Piqray) for the treatment of postmenopausal women, and men, with HR-positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer following progression on or after an endocrine-based regimen.

The Food and Drug Administration (FDA) approved ruxolitinib (Jakafi) for the treatment of patients 12 years or older with steroid-refractory acute graft-versus-host disease.

May is Skin Cancer Awareness month. What are some of the important conversations nurses should be having with their patients about the disease?

Funds Benefit Cancer Research in N.C. and Beyond

Nurses now have a wealth of new and updated resources to ensure their patients with prostate cancer can make the best treatment choices they can, thanks to the Prostate Cancer

Through her Bravery Bags program, Harding Cranford brings together members in the healthcare setting and the community to brighten patients’ days.

Investigators are working on expanding immunotherapy use for this patient population, and genetic testing will be more important than ever.

Compared to the general population, survivors of childhood cancer who live 5 or more years from diagnosis are at a higher risk for skin cancer.

Two new urine tests currently being investigated for bladder cancer detection and monitoring have demonstrated more than 90% sensitivity and specificity – highlighting the potential for addressing an unmet need among this patient population.

This was the first large, randomized clinical trial to show that diet can reduce the risk of dying from breast cancer.

Lenalidomide (Revlimid) significantly reduced the risk for smoldering multiple myeloma to progress to cancer among patients with moderate to high risk, according to findings from the phase II/III E3A06 trial to be presented at the 2019 ASCO Annual Meeting.

A group of researchers in the UK sought out to determine the efficacy of a reduced-dose regimen of oxaliplatin (Eloxatin) and capecitabine (Xeloda) in this patient population through the randomized, phase III GO2 clinical trial.

The FDA has approved the combination of venetoclax (Venclexta) and obinutuzumab (Gazyva) for the frontline treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

In this month's episode, we'll hear from one extraordinary oncology nurse who ran 100 miles for cancer research.

The FDA approved the combination use of avelumab plus axitinib for the first-line treatment of patients with advanced renal cell carcinoma.

While the FDA currently has no plans to ban textured breast implants, the agency did outline steps to ensure providers and patients are educated on breast implant-associated anaplastic large cell lymphoma (BIA-ALCL).

The anti-vaccination movement is causing outbreaks around the world, and may be even more dangerous for patients with cancer.

Children with severe sensorineural hearing loss (SNHL) from brain tumor treatment demonstrated greater reading difficulties compared with those who experienced mild or no hearing loss.

Event Supports Research through the V Foundation

When it comes to the treatment of patients with nonmetastatic castration-resistant prostate cancer (M0CRPC), 3 pivotal trials—SPARTAN, PROSPER, and most recently, ARAMIS—have demonstrated the safety and efficacy of second-generation targeted antiandrogens, said Richard (Rick) JaeBong Lee, MD, PhD.

While Lynch syndrome may be more common than originally thought, research continues to move forward to improve the outcomes of this patient population.

The FDA approved ramucirumab (Cyramza) as a single-agent treatment for patients with hepatocellular carcinoma (HCC) with an alpha fetoprotein (AFP) of ≥ 400 ng/mL and have been previously treated with sorafenib (Nexavar).